| Qiu, Meng |
NCT04988971: The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis |
|
|
| Recruiting | 3 | 90 | RoW | a compound glutamine capsule, a compound glutamine capsule simulated placebo | Meng Qiu | Mucositis, Chemotherapeutic Toxicity | 07/22 | 12/22 | | |
NCT05092113: The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis |
|
|
| Recruiting | 3 | 108 | RoW | a compound glutamine capsule/a compound glutamine capsule simulated placebo | Meng Qiu | Mucositis, Chemotherapeutic Toxicity | 12/22 | 12/22 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NCT06427005: Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC |
|
|
| Recruiting | 2 | 66 | RoW | Fruquintinib, Elunate, S-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, raltitrexed, thymidylate synthase inhibitor | West China Hospital | Fruquintinib, S-1, Raltitrexed | 06/24 | 12/24 | | |
CAPFOL, NCT05022030: First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes |
|
|
| Recruiting | 2 | 150 | RoW | mCapOX plus cetuximab, mFOLFOX6 plus cetuximab | West China Hospital, First Affiliated Hospital of Chongqing Medical University | Colo-rectal Cancer, Capecitabine, Cetuximab | 06/25 | 06/26 | | |
NCT04636008: Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer |
|
|
| Recruiting | 1/2 | 20 | RoW | Sintilimab, Hypofractionated Radiotherapy | West China Hospital, First Affiliated Hospital of Chongqing Medical University, Yunnan Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Chengdu Third People's Hospital, The Affiliated Hospital Of Southwest Medical University | Anti-PD-1 Antibody, Radiotherapy, Rectal Cancer, MSI-H, Mmr Deficiency | 11/22 | 11/22 | | |
NCT06243354: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation |
|
|
| Recruiting | 1/2 | 257 | RoW | Test product: HYP-2090PTSA | Sichuan Huiyu Pharmaceutical Co., Ltd | Safety, Tolerability, Efficacy | 12/25 | 12/25 | | |
NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 08/24 | 08/24 | | |
| Recruiting | 1/2 | 368 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT06200363: A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer |
|
|
| Recruiting | 1 | 15 | RoW | T3011, Regorafenib | West China Hospital | Advanced Colorectal Cancer | 11/24 | 11/24 | | |
NCT06200376: A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer |
|
|
| Recruiting | 1 | 10 | RoW | T3011 | West China Hospital | Malignant Ascites | 12/24 | 12/24 | | |
